133 related articles for article (PubMed ID: 2965972)
1. Suppressor deletion therapy: selective elimination of T suppressor cells in vivo using a hematoporphyrin conjugated monoclonal antibody permits animals to reject syngeneic tumor cells.
Steele JK; Liu D; Stammers AT; Whitney S; Levy JG
Cancer Immunol Immunother; 1988; 26(2):125-31. PubMed ID: 2965972
[TBL] [Abstract][Full Text] [Related]
2. Suppressor deletion therapy. Selective elimination of T suppressor cells using a hematoporphyrin-conjugated monoclonal antibody.
Steele JK; Liu D; Stammers AT; Deal H; Whitney S; Levy JG
Targeted Diagn Ther; 1988; 1():157-89. PubMed ID: 2980947
[No Abstract] [Full Text] [Related]
3. Isolation and characterization of a tumor-specific T suppressor factor from a T cell hybridoma.
Steele JK; Stammers AT; Levy JG
J Immunol; 1985 Apr; 134(4):2767-78. PubMed ID: 2579156
[TBL] [Abstract][Full Text] [Related]
4. Immunization of DBA/2 mice with a T cell hybridoma-derived TsF increases immune resistance to the syngeneic tumors P815 and L1210.
Steele JK; Singhai R; Stammers AT; Levy JG
J Immunol; 1986 Nov; 137(9):3025-30. PubMed ID: 3489783
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a monoclonal antibody directed to a T cell suppressor factor.
Maier T; Stammers AT; Levy JG
J Immunol; 1983 Oct; 131(4):1843-8. PubMed ID: 6413579
[TBL] [Abstract][Full Text] [Related]
6. Failure of anti-T cell monoclonal antibodies to prevent acute tumor allograft rejection is associated with their inability to deplete or inactivate T cells at the site of rejection.
Rakhmilevich AL
Transplantation; 1994 Jul; 58(1):72-80. PubMed ID: 7913562
[TBL] [Abstract][Full Text] [Related]
7. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
Hara H; Luo Y; Haruta Y; Seon BK
Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
[TBL] [Abstract][Full Text] [Related]
8. [The specific photodynamic effect of monoclonal antibodies conjugated with hematoporphyrin derivative on gastric cancer in vitro and in vivo].
Lin K
Zhonghua Yi Xue Za Zhi; 1989 Jan; 69(1):24-7, 4. PubMed ID: 2527079
[TBL] [Abstract][Full Text] [Related]
9. A monoclonal antibody raised to tumor-specific T cell-derived suppressor factors also recognizes T suppressor inducer factors of the 4-hydroxy-3-nitrophenyl acetyl hapten suppressor network.
Steele JK; Kawasaki H; Kuchroo VK; Minami M; Levy JG; Dorf ME
J Immunol; 1987 Oct; 139(8):2629-34. PubMed ID: 2443567
[TBL] [Abstract][Full Text] [Related]
10. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
Shimizu J; Yamazaki S; Sakaguchi S
J Immunol; 1999 Nov; 163(10):5211-8. PubMed ID: 10553041
[TBL] [Abstract][Full Text] [Related]
11. Characterization of an anti-idiotypic T cell hybridoma involved in the regulation of the immune response to the P815 mastocytoma.
Steele JK; Tench Stammers A; Chan A; Levy JG
J Immunol; 1986 Dec; 137(11):3550-6. PubMed ID: 3097127
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.
Streilein JW; Niederkorn JY
J Immunol; 1985 Mar; 134(3):1381-7. PubMed ID: 3155766
[TBL] [Abstract][Full Text] [Related]
13. [The antitumor activity of bovine serum albumin-mediated conjugate of hematoporphyrin derivative with antigastric cancer monoclonal antibody].
Zhang YJ; Wang NQ; Liu T; Dong ZW
Yao Xue Xue Bao; 1990; 25(12):886-90. PubMed ID: 2151781
[TBL] [Abstract][Full Text] [Related]
14. Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor.
Levraud JP; Pannetier C; Langlade-Demoyen P; Brichard V; Kourilsky P
J Exp Med; 1996 Feb; 183(2):439-49. PubMed ID: 8627157
[TBL] [Abstract][Full Text] [Related]
15. The immunotherapeutic effects in tumor-bearing mice of Ly-6 monoclonal antibodies.
Lu L; Palladino MA; DeLeo AB
J Immunol; 1989 Jan; 142(2):719-25. PubMed ID: 2783443
[TBL] [Abstract][Full Text] [Related]
16. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.
Carayanniotis G; Halloran PF
Cell Immunol; 1985 Mar; 91(1):100-10. PubMed ID: 2857596
[TBL] [Abstract][Full Text] [Related]
17. Preliminary characterization of a soluble immunosuppressive molecule from DBA/2 spleen cells using monoclonal antibody immunoadsorbence.
Steele JK; Stammers AT; Chan A; Maier T; Levy JG
Cell Immunol; 1985 Feb; 90(2):303-13. PubMed ID: 3155655
[TBL] [Abstract][Full Text] [Related]
18. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells.
Walker PR; Calzascia T; Schnuriger V; Scamuffa N; Saas P; de Tribolet N; Dietrich PY
J Immunol; 2000 Sep; 165(6):3128-35. PubMed ID: 10975826
[TBL] [Abstract][Full Text] [Related]
19. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
20. CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation.
Zhan Y; Corbett AJ; Brady JL; Sutherland RM; Lew AM
J Immunol; 2000 Oct; 165(7):3612-9. PubMed ID: 11034363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
